Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction

被引:9
|
作者
Harrison, GM
Davies, G
Martin, TA
Jiang, WG
Mason, MD
机构
[1] Univ Wales Coll Med, Dept Surg, Metastasis Res Grp, Cardiff CF14 4XN, S Glam, Wales
[2] Univ Wales Coll Med, Dept Clin Oncol, Cardiff CF4 4XN, S Glam, Wales
关键词
CD; ezrin; CD44; prostate cancer; endothelium;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD44 is a multifunctional cell surface adhesion molecule that has been implicated in tumour cell invasion and metastasis. Many cancer cell types as well as their metastases express high levels of CD44. Furthermore, the expression of certain CD44 variants has been linked with metastasis and tumour progression. It is known that ezrin a member of the ERM family of proteins can bind to CD44 and thus raises the possibility that it is involved in cell migration and metastasis. Therefore we examined the expression and distribution of CD44, its co-localisation and translocation with ezrin in prostate cancer cell lines as they interact with endothelial cells. Experimental results indicate prostate cancer cells express multiple CD44 isoforms that co-localise with ezrin in DU-145 and PC-3 prostate cancer cells. Treatment with hepatocyte growth factor (HGF/SF) resulted in up-regulation of CD44 and its co-translocation with ezrin during tumour-endothelial cell interactions. In addition, tumour cell adhesion to endothelial cells and their invasiveness was increased after exposure to HGF/SF, and can be blocked by the presence of anti-CD44 antibodies. It is concluded that CD44 and ezrin interact in endothelial cells and that they co-localise in the areas of tumour-endothelial contact. The CD44/ezrin complex plays a pivotal role in the capture and invasion of endothelial cells by prostate cancer cells.
引用
收藏
页码:935 / 940
页数:6
相关论文
共 50 条
  • [1] The role of CD44 and Ezrin during prostate cancer-endothelium interaction.
    Harrison, GM
    Jiang, WG
    Mason, MD
    BRITISH JOURNAL OF CANCER, 2002, 86 : S82 - S82
  • [2] Expression of CD44 isoforms in human skin cancer
    Simon, JC
    Heider, KH
    Dietrich, A
    Wutting, C
    Schopf, E
    Adolf, GR
    Ponta, H
    Herrlich, P
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (08) : 1394 - 1400
  • [3] Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region
    Verkaik, NS
    van Steenbrugge, GJ
    van Weerden, WM
    Bussemakers, MJ
    van der Kwast, TH
    LABORATORY INVESTIGATION, 2000, 80 (08) : 1291 - 1298
  • [4] Altered expression of CD44 in human prostate cancer during progression
    Nagabhushan, M
    Pretlow, TG
    Guo, YJ
    Amini, SB
    Pretlow, TP
    Sy, MS
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1996, 106 (05) : 647 - 651
  • [5] Expression of CD44 isoforms in human prostate tumor cell lines
    Stevens, JW
    Palechek, PL
    Griebling, TL
    Midura, RJ
    Rokhlin, OW
    Cohen, MB
    PROSTATE, 1996, 28 (03): : 153 - 161
  • [6] EXPRESSION OF CD44 MOLECULES AND CD44 LIGANDS DURING HUMAN THYMIC FETAL DEVELOPMENT - EXPRESSION OF CD44 ISOFORMS IS DEVELOPMENTALLY-REGULATED
    PATEL, DD
    HALE, LP
    WHICHARD, LP
    RADCLIFF, G
    MACKAY, CR
    HAYNES, BF
    INTERNATIONAL IMMUNOLOGY, 1995, 7 (02) : 277 - 286
  • [7] EXPRESSION OF CD44 ISOFORMS DURING ERYTHROID-DIFFERENTIATION
    COBOURN, SD
    LICKER, JK
    KURTZBERG, J
    TELEN, MJ
    CLINICAL RESEARCH, 1994, 42 (02): : A131 - A131
  • [8] CD44 ISOFORMS IN METASTATIC CANCER
    PONTA, H
    SLEEMAN, J
    DALL, P
    MOLL, J
    SHERMAN, L
    HERRLICH, P
    INVASION & METASTASIS, 1994, 14 (1-6): : 82 - 86
  • [9] EXPRESSION OF CD44 IN PROSTATE-CANCER CELLS
    LIU, AY
    CANCER LETTERS, 1994, 76 (01) : 63 - 69
  • [10] Decreased expression of CD44 in metastatic prostate cancer
    Noordzij, MA
    van Steenbrugge, GJ
    Schröder, FH
    Van der Kwast, TH
    INTERNATIONAL JOURNAL OF CANCER, 1999, 84 (05) : 478 - 483